ESR1 and breast carcinoma: In contrast, a retrospective evaluation of patients enrolled on two International Breast Cancer Study Group trials of chemoendocrine therapy in N0 EBC found that the benefit of ovarian suppression with goserelin in premenopausal patients with ER+ disease was exclusively confined to patients with LVI40.